Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)
Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1) / Fineberg N.A.; Hollander E.; Grant J.E.; Chamberlain S.R.; Drummond L.M.; Pellegrini L.; Laws K.R.; Wellsted D.; Reid J.; Nezgovorova V.; Baldwin D.S.. - In: COMPREHENSIVE PSYCHIATRY. - ISSN 0010-440X. - ELETTRONICO. - 116:(2022), pp. 152323.152323-152323.152332. [10.1016/j.comppsych.2022.152323]
Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)
Pellegrini L.;
2022
Abstract
Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
